NASDAQ: VRXAVeraxa Biotech Ag Stock
$1.37-0.04 (-2.84%)
Updated Sep 28, 2026
VRXA Price
$1.37
Fair Value Price
N/A
Market Cap
$193.73M
52 Week Low
$1.27
52 Week High
$27.36
P/E
-0.24x
P/B
-9.95x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$28.92k
Earnings
$6.74M
Gross Margin
N/A
Operating Margin
-286,029.75%
Profit Margin
-284,359.2%
Debt to Equity
-6.13
Operating Cash Flow
-$413k
Beta
0.33
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
VRXA Overview
Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company was founded in 2021 and is based in Heidelberg, Germany.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VRXA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VRXA
Ranked#182 of 464
Ranked#182 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.82 | A | |
| $7.81 | A | |
| $367.00 | A |
Be the first to know about important VRXA news, forecast changes, insider trades & much more!
VRXA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VRXA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VRXA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VRXA is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
VRXA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more VRXA due diligence checks available for Premium users.
Valuation
VRXA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.24x
Industry
15.4x
Market
47.54x
VRXA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-9.95x
Industry
5.19x
VRXA's financial health
Profit margin
Revenue
$0.0
Net Income
$180.5k
Profit Margin
0%
VRXA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VRXA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$272.3M
Liabilities
$286.7M
Debt to equity
-18.69
VRXA's short-term liabilities ($8.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VRXA's long-term liabilities ($111.08M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VRXA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VRXA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$149.3k
Investing
$0.0
Financing
$0.0
VRXA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VRXA vs Biotech Stocks
Veraxa Biotech Ag Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.